FDA says ‘threat of AMR’ behind Merck antibiotic label expansion 04-Jun-2019 By Ben Hargreaves The US FDA approves Merck’s application to expand the label of Zerbaxa for the treatment of hospital-acquired infections to address ‘global challenge’ of AMR.